Association of XPD Asp312Asn single nucleotide polymorphisms with oxaliplatin based chemotherapy
10.3760/cma.j.issn.1008-1372.2018.10.018
- VernacularTitle:XPD Asp312Asn单核酸多态性与奥沙利铂为基础方案化疗疗效的关联研究
- Author:
Jiangying KONG
1
;
Zhuo LIU
;
Jun LIU
Author Information
1. 浙江萧山医院检验科
- Keywords:
Colorectal neoplasms/DT;
Antineoplastic combined chemotherapy protocols;
Organoplatinum compounds/AD;
Xeroderma pigmentosum group D protein/GE;
Polymorphism,single nucleotide
- From:
Journal of Chinese Physician
2018;20(10):1510-1513
- CountryChina
- Language:Chinese
-
Abstract:
Objective This study was to determine the role of the Xeroderma pigmentosum group D (XPD) Asp312Asn polymorphism in predicting response to Oxaliplatin based chemotherapies and survival in patients with metastatic colorectal cancer.Methods This study enrolled a total of 106 patients treated with FOLFOX4 (n =72) or XELOX (n =34) regimen.The genotype of XPD Asp312Asn was analyzed by TaqMan probe based real-Time polymerase chain reaction (PCR).Logistic regression was used to predict the response to the treatments.Cox proportion hazards models and Kaplan-Meier method were applied to predict the survival.Results The effective rate of chemotherapy in 106 patients with colorectal cancer was 57.6％ (61/106).There was no significant difference in the distribution of G/G,G/A and A/A genotypes between the two groups (P ＞ 0.05).Multivariate survival analysis showed that the survival time of patients with A/A genotype,carcinoembryonic antigen (CEA) (＞5 ng/ml) and age (＞65 years) was relatively short,with statistical significance (P ＜ 0.05).Conclusions XPD Asp312Asn single nucleic acid polymorphism can be used as a predictor of survival in patients with metastatic colorectal cancer,but it is not associated with oxaliplatin sensitivity and needs further study.
